FDA reviewers plan to ask an advisory panel to examine safety concerns such as the risk of stroke, heart attack or cardiovascular-related death linked to Pfizer and Boehringer Ingelheim's lung drug Spiriva. The product is scheduled for expanded-approval review as a treatment for flare-ups of chronic obstructive pulmonary disease.

Full Story:

Related Summaries